Kiniksa Pharmaceuticals, Ltd. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Kiniksa Pharmaceuticals, Ltd. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Kiniksa Pharmaceuticals, Ltd. do? Business model and key facts
Get the full picture of Kiniksa Pharmaceuticals, Ltd.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 315
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Stocks related to Kiniksa Pharmaceuticals, Ltd.
Selected based on industry alignment and relative market positioning.
Events and news impacting Kiniksa Pharmaceuticals, Ltd. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Kiniksa Pharmaceuticals, Ltd. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
